LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Nieuwssentiment

By Acuity

67%

33%

331 / 374 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 dec 2025, 17:39 UTC

Belangrijke Marktbewegers

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15 dec 2025, 23:44 UTC

Marktinformatie

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15 dec 2025, 22:19 UTC

Marktinformatie

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15 dec 2025, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

15 dec 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15 dec 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15 dec 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

ServiceNow Completes Acquisition Of Moveworks >NOW

15 dec 2025, 21:00 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:36 UTC

Marktinformatie

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15 dec 2025, 20:31 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15 dec 2025, 20:27 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15 dec 2025, 20:15 UTC

Marktinformatie

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15 dec 2025, 19:22 UTC

Marktinformatie

Gold and Silver Gain to Start Week -- Market Talk

15 dec 2025, 18:37 UTC

Marktinformatie

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15 dec 2025, 18:29 UTC

Marktinformatie

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15 dec 2025, 17:58 UTC

Marktinformatie

Canada Housing Market In Search Of a Bottom -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 dec 2025, 17:36 UTC

Winsten

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15 dec 2025, 17:30 UTC

Acquisities, Fusies, Overnames

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

331 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.